TERUMO BLOOD AND CELL TECHNOLOGIES CORPORATE SESSION Streamlining process optimization from process development to commercial with automated solutions
Thursday, June 1, 2023 12:45 PM - 01:45 PM
Salle Maillot
Corporate Session
Streamlining process optimization from process development to commercial with automated solutions
Chair
Hugo Fabre, PhD, Head of Medical Affairs EMEA, Terumo Blood and Cell Technologies, Belgium
Speakers
Alex Klarer, Vice President, Business Strategy and Innovation, BioCentriq, United States
Matthew Smart, PhD, Lead Scientist, Cell and Gene Therapy Catapult, UK
Rebecca Lim, PhD, Senior VP – Scientific Affairs, Prescient Therapeutics, Australia
Process automation is key for any therapeutic provider moving towards commercial manufacturing. With an increasing number of technologies coming to market and new insights being gained, are we truly ready to set industry standards or should we focus on setting guidelines? As we explore this topic, key insights will be shared regarding making platform changes from manual or other automation platforms to take advantage of key technologies on the market, including addressing opportunities and challenges for scale-up and scale out. This session will also review how to manage transition of key quality metrics into automation, including data management of the process.
Chair
Hugo Fabre, PhD, Head of Medical Affairs EMEA, Terumo Blood and Cell Technologies, Belgium
Speakers
Alex Klarer, Vice President, Business Strategy and Innovation, BioCentriq, United States
Matthew Smart, PhD, Lead Scientist, Cell and Gene Therapy Catapult, UK
Rebecca Lim, PhD, Senior VP – Scientific Affairs, Prescient Therapeutics, Australia
Process automation is key for any therapeutic provider moving towards commercial manufacturing. With an increasing number of technologies coming to market and new insights being gained, are we truly ready to set industry standards or should we focus on setting guidelines? As we explore this topic, key insights will be shared regarding making platform changes from manual or other automation platforms to take advantage of key technologies on the market, including addressing opportunities and challenges for scale-up and scale out. This session will also review how to manage transition of key quality metrics into automation, including data management of the process.
Sponsored by:
